SAN FRANCISCO—If there’s one silver lining to the COVID-19 pandemic, it’s the amount of rapid innovation that occurred across medtech, biotech and healthcare to better serve patients who had either ...
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Freenome said Friday it plans to go public in a deal that ...
A blood-based colorectal cancer (CRC) screening test, SimpleScreen™, has shown a significant leap in performance, demonstrating high sensitivity for both malignant and advanced precancerous lesions ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood ...
(Reuters) - Blood test developer Freenome said on Thursday it has raised $254 million in a new funding round led by Swiss drugmaker Roche, to develop tests that can potentially detect multiple ...
SOUTH SAN FRANCISCO, Jan. 24, 2022 /PRNewswire/ -- Freenome, a privately held biotech company, presented at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) symposium last ...
– Final module for the first version of Freenome's colorectal cancer test has been submitted to FDA; approval and commercial launch anticipated in 2026 – – Availability of real-world patient and ...
Freenome is a biotechnology company that develops blood tests to detect early-stage cancer. The company uses artificial intelligence and genomics to analyze blood samples and identify cancerous cells.
Investors have poured boatloads of cash into liquid biopsy companies promising that their technology is the solution for non-invasive screening of early-stage cancer. In the latest mega funding round, ...
If liquid biopsies haven’t yet arrived, they’re definitely preparing the cabin for a timely descent. On Wednesday, San Francisco, California-based Freenome announced a $65 million Series A funding ...
Feb 15 (Reuters) - Blood test developer Freenome said on Thursday it has raised $254 million in a new funding round led by Swiss drugmaker Roche, to develop tests that can potentially detect multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results